Introduction {#sec1_1}
============

Primary sclerosing cholangitis (PSC) is an idiopathic, chronic hepatobiliary disorder characterized by inflammation with progressive obliterative fibrosis and focal dilatation of the intrahepatic and/or extrahepatic bile ducts, which can lead to biliary cirrhosis and end-stage liver disease \[[@B1]\]. PSC is more common in Caucasian male patients and has a strong association with inflammatory bowel disease, especially ulcerative colitis (UC). The incidence of PSC is given with 1.11/100,000 in adults \[[@B2]\]. There are reports that show 20% of patients to be asymptomatic and only diagnosed on routine screening revealing abnormal cholestatic liver enzymes \[[@B3], [@B4]\].

Sarcoidosis -- in contrast -- is an inflammatory systemic disease that typically occurs in two or more organs at the same time (e.g., lung, heart). In more than 90% of the cases, the lung is the main affected organ. A typical characteristic is the histological finding of non-caseating epithelioid granulomas in biopsies \[[@B5]\]. Similar to PSC, etiology of sarcoidosis is still unclear.

The following case shows how -- compared to PSC -- an easily treatable differential diagnosis like sarcoidosis can mimic symptoms of PCS when bile ducts are affected. The mechanism for this observation is based on the compression within the bile ducts due to inflammatory swelling with consecutive induction of a stenosis suggesting an image similar to stenosis in PSC patients.

Case Report {#sec1_2}
===========

An 18-year-old Caucasian male was presented as an outpatient to our hospital. The patient\'s complaints were abdominal pain in the right upper abdomen for 6 weeks. Moreover, cholestatic liver enzymes (alkaline phosphatase \[AP\] and γ-glutamyltransferase \[γ-GT\]) were also elevated. The patient developed vomiting and his leukocytes and CrP level increased. In 2015, he was diagnosed with (pan-)UC. He was in clinical remission and had no signs of a flare.

Laboratory findings for autoimmune hepatitis (ANA, LKM and SLA), primary biliary cholangitis (PBC) (AMA with subtype M~2~), PSC (x- and p-ANCA), and finally IgG4 in serum were negative. X-ray of his thorax and also echocardiography were normal. We only found a mild hyperinflation in the lung testing. Ultrasound (US) examination of the liver revealed dilatation of the main bile duct (DHC) of 12 mm with also irregularly dilated intrahepatic bile ducts with thickening of the wall resulting in a rich echo signaling of the duct wall. The rest of the liver parenchyma showed no pathologies. The following MR examination of the bile ducts and the pancreatic duct (magnetic resonance cholangiopancreatography) demonstrated a questionable stenosis in the prepapillary section of the DHC with concomitant narrowing of the intrahepatic bile ducts and slight enlargement of lymph nodes in the hepatic hilus and parapancreatic space. A typical finding for PSC was not described. However, endoscopic retrograde cholangiopancreatography revealed narrowed intrahepatic bile ducts, which suggested PSC. Interestingly, these findings were also present in the bifurcation of the DHC (Fig. [1](#F1){ref-type="fig"}). Brush cytology from the distal part of the bile duct showed a nonspecific acute inflammation. Liver biopsy was performed under sonographic control from the right liver lobule.

After liver biopsy, steroid treatment with 30 mg prednisolone orally per day was initiated with the intention to treat a possible IgG4-associated cholangitis. Following this, a quick response to treatment occurred. All initially increased laboratory findings normalized as shown in Table [1](#T1){ref-type="table"} for total bilirubin, γ-GT, AP, ASAT, and finally, ALAT. His pain in the right upper abdomen completely disappeared and US examination after 4 days of treatment revealed a significant narrowing of the formerly enlarged bile ducts as well of the intra- and extrahepatic bile ducts (Fig. [2](#F2){ref-type="fig"}).

Histology of the liver specimen (Fig. [3](#F3){ref-type="fig"}) showed no signs of PSC. In contrast, further workup suggested PBC. Moreover, differential diagnosis suggested also a possibility for hepatic sarcoidosis. However, AMA autoantibody was negative, while surprisingly, soluble interleukin-II receptor was markedly elevated with 1,305 U/mL (reference \< 623 U/mL) indicating a possibility for sarcoidosis. Because of this finding and due to a quick response to steroid treatment (decrease of cholestatic parameters, good clinical response, diminishing of abdominal pain, and significant decrease of the diameters of the bile ducts in US control), we excluded the possible diagnosis of PBC and continued steroid treatment of sarcoidosis manifested within the bile ducts.

Discussion {#sec1_3}
==========

Sarcoidosis is a rare disease with a prevalence of 46/100,000 in Germany. This disease is characterized by granulomatosis of various organs of unknown etiology, which mostly occurs (about 90%) within the lung and the lymphatic system. The liver and the bile ducts are involved in approximately 15--20% of the cases. Misdiagnosis can lead to misinterpretation of the findings as a malignant lesion, e.g., as a cholangiocellular carcinoma \[[@B6]\]. Furthermore, these findings can also lead to the misdiagnosis of PSC \[[@B7]\].

In our case, diagnosis of UC was known before and treated with *E. coli* Nissle 1917 due to intolerance to azathioprine and mesalazine. Indeed, the underlying UC suggested an association with PSC. Successful treatment with steroids and elevated levels of interleukin-II receptor as well as the histological findings of epithelioid-cellular granuloma with inflammation within the portal fields suggested involvement of the bile ducts caused by the assumed diagnosis of sarcoidosis. The standard of care therapy is systemic steroid treatment (prednisolone 0.5 mg/kg). Only in case of neurosarcoidosis are higher doses of steroids needed. In case of nonresponse, methotrexate or azathioprine is suggested. In case of unsuccessful treatment, there is consensus that anti-TNF-α (infliximab or adalimumab) can be considered as an effective alternative. Duration of treatment is at least 1 year. Although treatment with anti-TNF-α in Germany would be an off-label use for the treatment of sarcoidosis \[[@B8]\], our patient also suffered from UC, which can be treated with anti-TNF-α. Following therapy, it is recommended to closely monitor AP, γ-GT, and total bilirubin every 8--12 weeks.

In summary, our treatment as presented above is another reasonable option for patients with bile duct stenosis in case of sarcoidosis. Liver biopsy should be considered as gold standard in any case of suspicious condition and unclear diagnosis, especially when potentially invasive therapy is considered next.
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![Endoscopic retrograde cholangiopancreatography demonstrating constriction of the main duct bifurcation and the prepapillary region (marked with arrows).](crg-0013-0153-g01){#F1}

![Diameter of the main bile duct before prednisolone therapy initially measuring 12 mm (left panel) and following 4 days of prednisolone therapy with significant reduction to 6 mm (right panel).](crg-0013-0153-g02){#F2}

![Magnification of 200--400×, section 1 stained with HE, section 2 after immunohistochemistry against CK7 showing destruction of the bile ducts and the formation of epithelioid cells around the bile ducts.](crg-0013-0153-g03){#F3}

###### 

Laboratory findings

                     Normal range   June 2016   July 2016   August 2016 treatment day 1   August 2016 treatment day 4   March 2017   June 2017
  ------------------ -------------- ----------- ----------- ----------------------------- ----------------------------- ------------ -----------
  WBC, /nL           4--10          10.2        6.9         7.2                           8.06                          8.1          6.7
  Hb, g/dL           13.5--17.5     12.4        12.3        12.1                          11.9                          13.1         13.0
  ALT, U/L           \<50           29          27          20                            36                            23           76
  AST, U/L           \<50           29          25          43                            26                            34           101
  γ-GT, U/L          \<60           229         143         446                           194                           43           187
  AP, U/L            40--130        197         155         354                           154                           87           175
  Bilirubin, mg/dL   0.2--1.2       0.40        0.34        0.45                          0.44                          0.52         0.48
  CrP, mg/L          \<5            13.6        22.5        101.6                         10.5                          15.2         35.0
